Navigation Links
Double whammy: RNAi enhances lung cancer therapy
Date:3/20/2012

Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors (TKI). New research published in BioMed Central's open access journal BMC Medicine, shows that blocking production of epidermal growth factor receptor (EGFR) using RNAi, alongside TKI (or antibody therapy), could enhance the effect of TKI on NSCLC cell death, and slow cell growth.

There are 1.2 million new cases of lung cancer worldwide every year and about 75-85% of these are NSCLC. 10% of cases with NSCLC have a mutation in the gene responsible for making EGFR, and three quarters of these patients respond well to TKIs. However others are unresponsive, and, even for the people who responded at first, the cancer always ultimately becomes resistant to TKI therapy.

In an attempt to circumvent this problem researchers from Universitair Ziekenhuis Brussel, in Belgium, tested the effect of adding RNAi to standard TKI or antibody therapy in NSCLC cells. Proteins are made in the cell's cytoplasm, but DNA is stuck inside the nucleus. Consequently, in order to produce a protein, a cell must first copy the gene's DNA sequence, producing an intermediary molecule called RNA which is able to travel out of the nucleus to the cytoplasm. RNAi 'interferes' with the mechanism for producing proteins by blocking proper function of the intermediary RNA stage.

A team led by Prof De Grve and his co-worker, Gang Chen, found that the small interfering RNA (siRNA) molecule they designed was able to inhibit EGF protein production in all the NSCLC cell lines tested. It was also able to slow down cell growth and increase cell death (apoptosis) in all the cell lines although some responded better than others. When they tested siRNA alongside TKI and or monoclonal antibodies they discovered that the siRNA had an additional positive effect on the cell lines than the standard treatment alone.

Prof De Grve explained, "Some EGFR mutations were more sensitive to siRNA than others - we saw especially good results against the mutation in exon 19. We think that this reflects the fact that the growth of cells with this mutation is driven by EGFR, but that other mutations are not as active. A different EGFR mutation produces cells which cannot be inhibited by TKI, however even these cells were sensitive to siRNA."

These results provide hope for NSCLC patients with EGFR mutations, as it could potentially enhance TKI therapy. It may also help those who do not respond to TKI, or who have become resistant to TKI therapy. Additionally this treatment may benefit another group of patients where the gene for EGFR is too active in their cancer and too much EGFR is produced.


'/>"/>

Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-203-192-2370
BioMed Central
Source:Eurekalert

Related medicine news :

1. U.S. Deaths From Gastro Infections Doubled Over 8 Years: CDC
2. New drug, Vemurafenib, doubles survival of metastatic melanoma patients
3. New street drug bath salts packs double punch
4. New combo of chemo and well-known malaria drug delivers double punch to tumors
5. Pot Use Could Double Risk of Car Crash, Research Shows
6. Rate of physician referrals nearly doubled
7. Targeting EETs to treat cardiovascular disease may prove a double-edged sword
8. Scientists may be able to double efficacy of radiation therapy
9. Asthma rates double for WTC first responders
10. Use of opioid painkillers for abdominal pain has more than doubled
11. STD Complication May Double Infertility Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households ... mail from USA Medical Prescription Assistance Program. They are customized to reflect the ... package will include a ready-to-use, state-themed card and, in the near future, material ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion Coalition ... an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data collection. ... 1, 2016. , Sarcopenia is defined as a combination of low muscle mass and ...
(Date:4/28/2016)... ... April 28, 2016 , ... North Hollywood dentist , Dr. Hamid ... is essential when it comes to dental accidents or critical dental problems. These issues ... losing a tooth. Toothaches, knocked-out teeth, chipped teeth, and many other issues can lead ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... , ... April 28, 2016 , ... For many, a diet is only as good ... if it does not look good. In addition, an individual cannot deny the importance of ... , The team, therefore, has worked to create a product range that could entice people ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology: